Repros Therapeutics — Zonagen — Shareholder Meeting (September 2004)
17 slides from Repros Therapeutics's shareholder meeting presentation, Sep 29, 2004
Slide 1: Zonagen Annual Meeting September 29, 2004
Zonagen Annual Meeting September 29, 2004
Slide 2: Forward-looking statements
This presentation contains forward-looking statements and information regarding the future performance and actions of Zonagen that involve risks and uncertainties that could cause actual results and actions to differ materially from those set forth in the presentation, including, but not limited to,
Slide 3: Company Overview Post Dutch Tender Offer
COMPANY OVERVIEW POST DUTCH TENDER OFFER Four employees President, CFO, Chief Scientist, Office Manager Company operates in near virtual fashion Lower overhead cost Use of CROs New focused board Currently seven members Experience includes FDA, big pharma and biotech
Slide 4: Key Financial Data
KEY FINANCIAL DATA Cash @ 6/30/04 = $7.62 million Projected 2004 cash burn = $5.2 million Approx. 5 million shares outstanding
Slide 5: Product Pipeline
PRODUCT PIPELINE Research PreClin Progenta Androxal Research PreClin Ph I/II Ph II Ph III Uterine Fibroids Uterine Fibroids Endometriosis Endometriosis Breast Cancer Breast Cancer Testosterone Deficiency Testosterone Deficiency HRT HRT Research PreClin Progenta Androxal Research PreClin Ph I/II Ph I
Slide 6: Stock Performance Since October 1, 2003
STOCK PERFORMANCE SINCE OCTOBER 1, 2003
Slide 7: Progenta Overview
PROGENTA OVERVIEW New class of [ANTIPROGESTIN] progesterone receptor modulator Potential indications: uterine fibroids, endometriosis, breast cancer and HRT Potential significant advantages over existing therapies No loss of bone mineral density in clinical trials No other drugs available for fibroi
Slide 8: Uterine Fibroids
UTERINE FIBROIDS 30% of women > Age 30 8,000,000 women in US experience abnormal bleeding due to fibroids Most frequent indication for hysterectomy $1-$1.5 Billion Spent Annually in US No current drug cure
Slide 9: Phase I/II Uterine Fibroid Trial
PHASE I/II UTERINE FIBROID TRIAL Design: N=30 Women with signs and symptoms of uterine fibroids Doses of 0, 12.5, 25, 50 mg Progenta and Lupron Treated for 1 month with potential for 2 month extension Endpoints: Safety, PK and efficacy trial Reduction in fibroid size Positive change in hematocrit Bo
Slide 10: Endometriosis
ENDOMETRIOSIS 5 million women in US affected 10-15% of Women Ages 25-44 No acceptable chronic therapy Chronic GnRH agonist therapy results in bone loss and severe hot flashes Laparoscopic surgery and pregnancy provide relief
Slide 11: Testosterone Replacement Market
TESTOSTERONE REPLACEMENT MARKET Gels Transdermal Orals Injectables 71.5 14.5 2.4 11.6 2003 = $375MM Market Opportunity Source: IMS Health
Slide 12: How Androxal Works
HOW ANDROXAL WORKS Hypothalamus Pituitary Axis Testes Estrogen Androxal LH Surge Increased Testosterone Secretion
Slide 13: Androxal & Androgel Effects on Total Testosterone
ANDROXAL & ANDROGEL EFFECTS ON TOTAL TESTOSTERONE P=0.0053 P=0.0002 P=0.0005 P=0.043 P=0.019
Slide 14: Androxal & Androgel Effects on Peak Testosterone
ANDROXAL & ANDROGEL EFFECTS ON PEAK TESTOSTERONE 0 0.5 1 2 12 24 Androgel 192 325 457 523 523 635 Androgel 270 470 373 435 351 401 Androgel 651 761 798 776 1036 1036 Androgel 1163 1221 1046 1321 1293 1113 Androgel 568 1016 1268 1493 2552 1183 50 mg 347 389 470 419 402 482 50 mg 768 770 883 720 626 1
Slide 15: Androxal Intellectual Property
ANDROXAL INTELLECTUAL PROPERTY Drug composition patent application filed Currently involved in IP dispute Other party holds patent on treatment of androgen deficiency using selective Clomid and its isomers The PTO has reexamined the other patent and has rejected all claims Other party has until Nov.
Slide 16: 2004 Major Milestones
2004 MAJOR MILESTONES First Half Commenced European Phase I/II Uterine Fibroid Study Reported US Androxal Phase I/II Results Second Half Report Progenta Phase I/II Results for Fibroids Publish Results of Primate Endometriosis Study Progenta Pre-IND Meeting Androxal End-of-Study Meeting
Slide 17: 2005 Major Milestones
2005 MAJOR MILESTONES First Half Commence US Phase II/III Uterine Fibroid Study Commence US Phase II Endometriosis Study US Phase II/III Androxal Study Second Half Report Progenta Phase II/III Results for Fibroids Report Progenta Phase II Results for Endometriosis Report Androxal Phase II/III Result